Clinical Trial Results:
A Multicenter, Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged >=13 Years
Summary
|
|
EudraCT number |
2010-020083-38 |
Trial protocol |
HU DE LT DK FR IT ES PL |
Global end of trial date |
14 Sep 2012
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
24 Mar 2016
|
First version publication date |
24 Mar 2016
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
NV25118
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01050257 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
F. Hoffmann-La Roche AG
|
||
Sponsor organisation address |
Grenzacherstrasse 124, Basel, Switzerland, CH-4070
|
||
Public contact |
Roche Trial Information Hotline, F. Hoffmann-La Roche AG, +41 61 6878333, global.trial_information@roche.com
|
||
Scientific contact |
Roche Trial Information Hotline, F. Hoffmann-La Roche AG, +41 61 6878333, global.trial_information@roche.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
14 Sep 2012
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
14 Sep 2012
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
14 Sep 2012
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
To evaluate the safety of oseltamivir administered by intravenous infusion in the treatment of influenza (seasonal or pandemic [H1N1] 2009 influenza).
|
||
Protection of trial subjects |
The study was conducted in accordance with the Declaration of Helsinki and good clinical practices (GCP) guidelines, or with the laws of the country if these afforded greater protection. Written informed consent for participation in the study was obtained prior to performing any study-specific assessments or procedures. Participants had the right to withdraw from the study at any time for any reason.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
15 Jan 2010
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Romania: 10
|
||
Country: Number of subjects enrolled |
France: 2
|
||
Country: Number of subjects enrolled |
Hungary: 34
|
||
Country: Number of subjects enrolled |
Italy: 6
|
||
Country: Number of subjects enrolled |
Lithuania: 2
|
||
Country: Number of subjects enrolled |
United States: 64
|
||
Worldwide total number of subjects |
118
|
||
EEA total number of subjects |
54
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
4
|
||
Adults (18-64 years) |
90
|
||
From 65 to 84 years |
24
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Recruitment details |
Of the 122 participants screened, 118 were enrolled into the study. Participants were enrolled at 38 active centers in 6 countries. | ||||||||||||||||||||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Screening details |
This study included a 5-day treatment period and an optional extension treatment period. Participants were considered to have completed treatment if they completed the 5-day course of treatment (IV and/or oral). | ||||||||||||||||||||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Period 1 title |
Period 1 (overall period)
|
||||||||||||||||||||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||||||||||||||||||||
Roles blinded |
Investigator, Subject | ||||||||||||||||||||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Oseltamivir 100 mg IV bid | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Participants received 100 mg of oseltamivir administered by controlled IV infusion over 2 hours, twice daily (bid), for 5 days. A minimum of 6 doses (3 days) of IV oseltamivir was required. Thereafter, at the discretion of the investigator, participants had the option of completing the 5-day course with either IV or oral oseltamivir. | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Oseltamivir (intravenous)
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
Ro 64-0796/F09-01
|
||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
Oseltamivir phosphate
|
||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder for solution for infusion
|
||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Intravenous oseltamivir was administered by slow infusion over 2 hours, every 12 hours.
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Oseltamivir capsules (75 mg)
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
Oseltamivir phosphate
|
||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule, hard
|
||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Oral oseltamivir was administered as 75 mg capsules for the randomized treatment groups. Participants randomized to the 100 mg IV treatment group who switched to oral therapy received one 75 mg capsule twice daily.
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule, hard
|
||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
One placebo capsule was administered twice daily to participants randomized to the 100 mg IV treatment group who switched to oral therapy.
|
||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Oseltamivir 200 mg IV bid | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Participants received 200 mg of oseltamivir administered by controlled IV infusion over 2 hours, every 12 hours, for 5 days. A minimum of 6 doses (3 days) of IV oseltamivir was required. Thereafter, at the discretion of the investigator, participants had the option of completing the 5-day course with either IV or oral oseltamivir. | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Oseltamivir (intravenous)
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
Ro 64-0796/F09-01
|
||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
Oseltamivir phosphate
|
||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder for solution for infusion
|
||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Intravenous oseltamivir was administered by slow infusion over 2 hours, every 12 hours.
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Oseltamivir capsules (75 mg)
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
Oseltamivir phosphate
|
||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule, hard
|
||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Oral oseltamivir was administered as 75 mg capsules for the randomized treatment groups. Participants randomized to the 200 mg IV treatment group who switched to oral therapy received two 75 mg capsules twice daily.
|
||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Oseltamivir open-label | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Participants with moderate/severe renal impairment or renal failure were offered a 5-day course of treatment with IV oseltamivir at a dosage of 40 mg bid or 40 mg once daily (qd), depending on their creatinine clearance range and whether or not they were on continuous renal replacement therapy (CRRT). For participants with moderate or severe renal impairment who did not receive the full treatment course intravenously, oral oseltamivir was supplied as 30 mg capsules in an open-label fashion. Participants on hemodialysis (HD) received 25 mg IV after every HD session. Participants on continuous ambulatory peritoneal dialysis (CAPD) received a single IV dose of 40 mg. For participants on HD or CAPD who switched to oral dosing during the treatment extension period, oral oseltamivir was supplied as 30 mg capsules. | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Oseltamivir (intravenous)
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
Ro 64-0796/F09-01
|
||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
Oseltamivir phosphate
|
||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder for solution for infusion
|
||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
In participants with moderate renal impairment, 40 mg dose was given as a slow IV infusion over 2 hours every 12 hours. In participants with severe renal impairment, 40 mg dose was given as a slow IV infusion over 2 hours every 24 hours.
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Oseltamivir capsules (30 mg)
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
oseltamivir phosphate
|
||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule, hard
|
||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
For participants with moderate or severe renal impairment who did not receive the full treatment course intravenously, oral oseltamivir was supplied as 30 mg capsules in an open-label fashion. Participants with moderate renal impairment received one 30 mg capsule twice daily, while participants with severe renal impairment received one 30 mg capsule once daily.
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Oseltamivir 100 mg IV bid
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received 100 mg of oseltamivir administered by controlled IV infusion over 2 hours, twice daily (bid), for 5 days. A minimum of 6 doses (3 days) of IV oseltamivir was required. Thereafter, at the discretion of the investigator, participants had the option of completing the 5-day course with either IV or oral oseltamivir. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Oseltamivir 200 mg IV bid
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received 200 mg of oseltamivir administered by controlled IV infusion over 2 hours, every 12 hours, for 5 days. A minimum of 6 doses (3 days) of IV oseltamivir was required. Thereafter, at the discretion of the investigator, participants had the option of completing the 5-day course with either IV or oral oseltamivir. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Oseltamivir open-label
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants with moderate/severe renal impairment or renal failure were offered a 5-day course of treatment with IV oseltamivir at a dosage of 40 mg bid or 40 mg once daily (qd), depending on their creatinine clearance range and whether or not they were on continuous renal replacement therapy (CRRT). For participants with moderate or severe renal impairment who did not receive the full treatment course intravenously, oral oseltamivir was supplied as 30 mg capsules in an open-label fashion. Participants on hemodialysis (HD) received 25 mg IV after every HD session. Participants on continuous ambulatory peritoneal dialysis (CAPD) received a single IV dose of 40 mg. For participants on HD or CAPD who switched to oral dosing during the treatment extension period, oral oseltamivir was supplied as 30 mg capsules. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Oseltamivir 100 mg IV bid
|
||
Reporting group description |
Participants received 100 mg of oseltamivir administered by controlled IV infusion over 2 hours, twice daily (bid), for 5 days. A minimum of 6 doses (3 days) of IV oseltamivir was required. Thereafter, at the discretion of the investigator, participants had the option of completing the 5-day course with either IV or oral oseltamivir. | ||
Reporting group title |
Oseltamivir 200 mg IV bid
|
||
Reporting group description |
Participants received 200 mg of oseltamivir administered by controlled IV infusion over 2 hours, every 12 hours, for 5 days. A minimum of 6 doses (3 days) of IV oseltamivir was required. Thereafter, at the discretion of the investigator, participants had the option of completing the 5-day course with either IV or oral oseltamivir. | ||
Reporting group title |
Oseltamivir open-label
|
||
Reporting group description |
Participants with moderate/severe renal impairment or renal failure were offered a 5-day course of treatment with IV oseltamivir at a dosage of 40 mg bid or 40 mg once daily (qd), depending on their creatinine clearance range and whether or not they were on continuous renal replacement therapy (CRRT). For participants with moderate or severe renal impairment who did not receive the full treatment course intravenously, oral oseltamivir was supplied as 30 mg capsules in an open-label fashion. Participants on hemodialysis (HD) received 25 mg IV after every HD session. Participants on continuous ambulatory peritoneal dialysis (CAPD) received a single IV dose of 40 mg. For participants on HD or CAPD who switched to oral dosing during the treatment extension period, oral oseltamivir was supplied as 30 mg capsules. | ||
Subject analysis set title |
Safety Population
|
||
Subject analysis set type |
Safety analysis | ||
Subject analysis set description |
The safety population included all participants who received at least one dose of study medication (IV or oral) and had a safety assessment performed after initiation of treatment.
|
||
Subject analysis set title |
Intent-to-Treat Population
|
||
Subject analysis set type |
Intention-to-treat | ||
Subject analysis set description |
All participants who received at least one dose of study medication (IV or oral) were included in the intent-to-treat (ITT) population.
|
||
Subject analysis set title |
Intent-to-Treat Influenza Infected (ITTI) Population
|
||
Subject analysis set type |
Intention-to-treat | ||
Subject analysis set description |
The subset of participants in the ITT population who had laboratory confirmation of influenza infection (positive viral culture or RT-PCR), excluding participants infected with oseltamivir resistant influenza at baseline (as determined by phenotypic and, where necessary, genotypic testing), were included in the intent-to-treat infected (ITTI) population. The ITTI population was the primary population for the analysis of the efficacy variables.
|
||
Subject analysis set title |
Oseltamivir open-label 40 mg IV bid
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Participants with moderate/severe renal impairment not on CRRT with creatinine clearance (CrCL) >30 to 60 millilitre/minute (mL/min), received intravenous oseltamivir at a dose of 40 mg bid. Participants who were on CRRT and who had CRRTCL ± CrCL >30 mL/min also received intravenous oseltamivir at a dose of 40 mg bid.
|
||
Subject analysis set title |
Oseltamivir open-label 40 mg IV qd
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Participants with moderate/severe renal impairment not on CRRT with CrCl 10 to 30 mL/min, received intravenous oseltamivir at a dose of 40 mg daily. Participants who were on CRRT and who had CRRTCL ± CrCL 10 to 30 mL/min also received intravenous oseltamivir at a dose of 40 mg daily.
|
|
|||||||||||||||||||||||||||||||||||||
End point title |
Number of participants with any adverse events or serious adverse events [1] | ||||||||||||||||||||||||||||||||||||
End point description |
An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is any experience that suggests a significant hazard, contraindication, side effect or precaution that results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. On treatment = AEs that started between the day of first dose and within 2 days after the last dose. Off treatment = AEs that started more than 2 days after the last dose of study drug.
|
||||||||||||||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
Up to Day 30
|
||||||||||||||||||||||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Statistical analysis was not carried out for the primary end point. |
|||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Number of participants with viral shedding by culture | ||||||||||||||||||||||||||||||||||||
End point description |
Viral culturing from throat and nasal swabs was used to confirm the occurrence of viral shedding. The presence of viral shedding was determined by means of positive viral culture = log10 TCID50 > 0.5 TCID50 = 50% tissue culture infective dose. Only participants with data available at particular timepoint were analysed. n = the number of participants analysed at the given time point.
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
Days 1, 4, 6, 11, 15, and 30
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Number of participants with viral shedding by reverse transcriptase polymerase chain reaction | ||||||||||||||||||||||||||||||||||||
End point description |
Nasal and throat swabs from participants were used to evaluate the occurrence of viral shedding by reverse transcriptase polymerase chain reaction (RT-PCR) (log 10 copies/mL). Only participants with data available at particular time point were analysed. n = the number of participants analysed at the given time point.
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
Days 1, 4, 6, 11, 15, and 30
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Mean change from baseline in influenza titer by culture at Day 4 | ||||||||||||||||||||
End point description |
Throat and nasal swabs from participants were used to evaluate viral load (amount of virus present) determined by culture. Positive culture was indicated by a log 10 median TCID50 > 0.5. A negative change from baseline indicated improvement (less virus present). n = the number of participants analysed at the given time point.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline (Day 0) and Day 4
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Mean change from baseline in body temperature until last value | ||||||||||||||||
End point description |
Body temperature was recorded twice daily from baseline up to Day 30. Body temperature is presented as the change from baseline until the last value recorded.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline, up to Day 30
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of participants who had fever during the study | ||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Fever is defined as a body temperature >=37.8 degrees Celcius. The number of participants with fever (on a 12-hourly basis) was reported. Only participants with fever at particular time point were analysed. n = the number of participants analysed at the given time point.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Baseline and Hours 12, 24, 36, 48, 60, 72, 84, 96 and 108
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Time to resolution of fever for participants who had a fever at baseline | ||||||||||||||||
End point description |
Participants who had fever at baseline (based on baseline temperature) were included in the time to resolution of fever (afebrile state) analysis. Fever was defined as a temperature of >= 37.8 degrees Celsius. Resolution of fever was a temperature <=37.2 for at least 21.5 hours.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline, Up to Day 30
|
||||||||||||||||
|
|||||||||||||||||
Notes [2] - Median could not be calculated due to small number of participants analysed (1 participant censored) |
|||||||||||||||||
Statistical analysis title |
Oseltamivir 200 mg vs. Oseltamivir 100 mg | ||||||||||||||||
Statistical analysis description |
The time to resolution of fever was compared for the two treatment groups (200 mg oseltamivir and 100 mg oseltamivir). Median time was estimated from the Kaplan-Meier curve. Wilcoxon test was used for testing the homogeneity of the two survival curves.
|
||||||||||||||||
Comparison groups |
Oseltamivir 100 mg IV bid v Oseltamivir 200 mg IV bid
|
||||||||||||||||
Number of subjects included in analysis |
13
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
other | ||||||||||||||||
P-value |
= 0.671 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Parameter type |
Median difference (final values) | ||||||||||||||||
Point estimate |
-6.8
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
95% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-65 | ||||||||||||||||
upper limit |
29.7 |
|
|||||||||||||||||||||||||||||
End point title |
Number of participants with influenza symptoms | ||||||||||||||||||||||||||||
End point description |
Influenza symptoms included nasal congestion, sore throat, cough, aches and pains, fatigue, chills/sweats (feverish), headache, vomiting, and diarrhea. The number of participants with influenza symptoms by study day is reported. Only participants with influenza symptoms at particular time point were analysed. n = the number of participants analysed at the given time point.
|
||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||
End point timeframe |
Days 1, 11, 15, 30
|
||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Number of participants with viral resistance | ||||||||||||
End point description |
Nasal and Throat swabs were collected on Days 1, 4, 6, 11, 15 and 30 and were sent to a central laboratory for testing. Viral resistance was determined by phenotypic and genotypic testing.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to Day 30
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||
End point title |
Calculated creatinine clearance [3] | |||||||||||||||||||||||||
End point description |
Creatinine Clearance (CrCl) was estimated according to Cockcroft-Gault for participants >=18 years and according to Schwartz equation for participants <18 years. Calculated creatinine clearance measures the rate creatinine (substance formed from metabolism of creatine) is cleared from blood by the kidneys.
|
|||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||
End point timeframe |
Screening
|
|||||||||||||||||||||||||
Notes [3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The subject analysis sets - Oseltamivir open-label 40 mg IV bid and Oseltamivir open-label 40 mg IV qd contain participants from the Oseltamivir open-label arm reported in the baseline period. Data for the Oseltamivir open-label arm, for this end point, is represented via the Oseltamivir open-label 40 mg IV bid and Oseltamivir open-label 40 mg IV qd subject analysis sets. |
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||
End point title |
Area under the curve at steady state of oseltamivir and oseltamivir carboxylate [4] | ||||||||||||||||||||||||||||||
End point description |
The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The area under the curve at steady state (AUCss) is the area under the curve during the steady-state period. Participants treated with oseltamivir and who had measurable concentrations of oseltamivir and oseltamivir carboxylate were included in the pharmacokinetic (PK) analysis unless major protocol deviations or unavailability of information occurred which could interfere with PK evaluation.
|
||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||
End point timeframe |
Day 1 to Day 5
|
||||||||||||||||||||||||||||||
Notes [4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The subject analysis sets - Oseltamivir open-label 40 mg IV bid and Oseltamivir open-label 40 mg IV qd contain participants from the Oseltamivir open-label arm reported in the baseline period. Data for the Oseltamivir open-label arm, for this end point, is represented via the Oseltamivir open-label 40 mg IV bid and Oseltamivir open-label 40 mg IV qd subject analysis sets. |
|||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||
End point title |
Maximum concentration at steady state and trough concentration at the end of the dosing interval of oseltamivir and oseltamivir carboxylate [5] | ||||||||||||||||||||||||||||||||||||||||
End point description |
The Plasma Concentration (Cmax) is defined as the maximum observed drug/analyte concentration. The trough concentration is defined as the plasma level of a drug measured just before the next dose. Trough concentration at the end of the dosing interval (Ctr) values were computed over the 12-hour or 24-hour period depending on the inter-dose interval of each participant. Participants treated with oseltamivir and who had measurable concentrations of oseltamivir and oseltamivir carboxylate were included in the PK analysis unless major protocol deviations or unavailability of information occurred which could interfere with PK evaluation.
|
||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 1 to Day 5
|
||||||||||||||||||||||||||||||||||||||||
Notes [5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The subject analysis sets - Oseltamivir open-label 40 mg IV bid and Oseltamivir open-label 40 mg IV qd contain participants from the Oseltamivir open-label arm reported in the baseline period. Data for the Oseltamivir open-label arm, for this end point, is represented via the Oseltamivir open-label 40 mg IV bid and Oseltamivir open-label 40 mg IV qd subject analysis sets. |
|||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Within 2 days after last dose of treatment
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
An AE can be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. All AEs (related and unrelated) occurring during the treatment period were reported.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
15.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Oseltamivir 100 mg IV bid
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received 100 mg of oseltamivir administered by controlled IV infusion over 2 hours, every 12 hours, for 5 days. A minimum of 6 doses (3 days) of IV oseltamivir was required. Thereafter, at the discretion of the investigator, participants had the option of completing the 5-day course with either IV or oral oseltamivir. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Oseltamivir 200 mg IV bid
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received 200 mg of oseltamivir administered by controlled IV infusion over 2 hours, every 12 hours, for 5 days. A minimum of 6 doses (3 days) of IV oseltamivir was required. Thereafter, at the discretion of the investigator, participants had the option of completing the 5-day course with either IV or oral oseltamivir. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Oseltamivir open-label
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants with moderate/severe renal impairment or renal failure were offered a 5-day course of treatment with IV oseltamivir at a dosage of 40 mg bid or 40 mg once daily qd, depending on their creatinine clearance range and whether or not they were on CRRT. For participants with moderate or severe renal impairment who did not receive the full treatment course intravenously, oral oseltamivir was supplied as 30 mg capsules in an open-label fashion. Participants on HD received 25 mg IV after every HD session. Participants on CAPD received a single IV dose of 40 mg. For participants on HD or CAPD who switched to oral dosing during the treatment extension period, oral oseltamivir was supplied as 30 mg capsules. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
20 May 2010 |
Enrollment to participants outside of the US was opened. Participants with renal impairment and renal failure were enrolled and treated. New guidelines for the preparation of IV investigational product for the randomized population (change in infusion volume from 50 mL to 100 mL) were provided. |
||
14 Oct 2011 |
Participants undergoing HD and CAPD could be switched from IV to oral dosing. Oral dosing recommendations for participants with renal impairment were updated as a result of the availability of lower dose oseltamivir capsules and the desire to better align oral dosing recommendations with those anticipated for IV oseltamivir. This amendment allowed enrollment of participants up to 144 hours after the onset of first influenza symptoms to allow for the enrollment of participants who may have started on oral oseltamivir and whose condition then necessitated IV oseltamivir. The creatinine clearance cutoff value in moderate renal impairment was corrected from 50 to 60 mL/min to be consistent with available regulatory guidance and prior clinical studies of oseltamivir in participants with renal impairment. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |